8.2 MNT for Diabetes Mellitus and Endocrine Disorders

Diabetes mellitus represents a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is directly associated with long-term damage, dysfunction, and failure of various organ systems, especially the eyes, kidneys, nerves, heart, and blood vessels. In clinical dietetics, Medical Nutrition Therapy (MNT) is an essential component of comprehensive diabetes management, capable of reducing glycated hemoglobin ($\text{HbA1c}$) by 1.0% to 2.0% when delivered by a licensed Registered Nutritionist-Dietitian (RND).

---

Pathophysiology and Classification of Diabetes Mellitus

Diabetes is classified into four clinical categories based on underlying etiology and pathophysiological mechanisms:

1. Type 1 Diabetes Mellitus (T1DM)

• Etiology: Cellular-mediated autoimmune destruction of pancreatic $\beta$-cells within the islets of Langerhans, mediated by autoantibodies against glutamic acid decarboxylase (anti-GAD65), islet cell antibodies (ICA512/IA-2), and insulin autoantibodies (IAA).
• Pathophysiology: Absolute insulin deficiency. Without exogenous insulin administration, unrestrained lipolysis and hepatic ketogenesis occur, precipitating life-threatening Diabetic Ketoacidosis (DKA).
• Clinical Presentation: Rapid onset in children or young adults characterized by the classic osmotic triad: polyuria, polydipsia, and polyphagia, accompanied by dramatic unintentional weight loss, ketonuria, metabolic acidosis (anion gap $> 12\text{ mEq/L}$), and deep, rapid Kussmaul respirations.

2. Type 2 Diabetes Mellitus (T2DM)

• Etiology: Progressive loss of adequate $\beta$-cell insulin secretion frequently on the background of peripheral insulin resistance (skeletal muscle, adipose tissue, and liver).
• Pathophysiology: Characterized by hyperinsulinemia during early stages, which gradually fails as $\beta$-cells undergo secretory exhaustion and glucolipotoxicity. Hepatic gluconeogenesis proceeds unchecked, and skeletal muscle glucose uptake via GLUT-4 transporters is severely blunted.
• Acute Complication: Prone to Hyperglycemic Hyperosmolar State (HHS) rather than DKA, characterized by profound hyperglycemia ($> 600\text{ mg/dL}$), serum hyperosmolality ($> 320\text{ mOsm/kg}$), and severe dehydration without significant ketoacidosis, due to residual endogenous insulin sufficient to suppress lipolysis.

3. Gestational Diabetes Mellitus (GDM)

• Etiology: Hyperglycemia recognized during the second or third trimester of pregnancy that is not clearly overt preexisting type 1 or type 2 diabetes.
• Pathophysiology: Human placental lactogen (hPL), progesterone, cortisol, and prolactin reach peak circulating levels between 24 and 28 weeks of gestation, producing physiological insulin resistance. When maternal pancreatic $\beta$-cells cannot mount a compensatory 2- to 3-fold increase in insulin secretion, maternal and fetal hyperglycemia ensue.
• Diagnostic Protocol (One-Step 75g OGTT): Endorsed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and the American Diabetes Association (ADA). Administered in the morning after an 8- to 14-hour overnight fast at 24–28 weeks of gestation:

$\text{Fasting Plasma Glucose (FPG)} \ge 92\text{ mg/dL } (5.1\text{ mmol/L})$ $\text{1-Hour Plasma Glucose} \ge 180\text{ mg/dL } (10.0\text{ mmol/L})$ $\text{2-Hour Plasma Glucose} \ge 153\text{ mg/dL } (8.5\text{ mmol/L})$

Diagnostic Criterion: Meeting or exceeding any single threshold confirms the diagnosis of GDM.

4. Specific Types Due to Other Causes

Monogenic diabetes syndromes (MODY, neonatal diabetes), diseases of the exocrine pancreas (cystic fibrosis, chronic pancreatitis / Type 3c diabetes), and drug- or chemical-induced diabetes (glucocorticoid therapy, immunosuppression following organ transplantation, antiretroviral regimens).

---

Diagnostic Criteria for Prediabetes and Overt Diabetes Mellitus

Standard diagnostic cut-offs from the American Diabetes Association Standards of Care, also used in Philippine clinical practice, are outlined below:

In the absence of unequivocal symptomatic hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss), diagnosis requires two abnormal test results from the same sample or two separate test samples.

---

Medical Nutrition Therapy Goals and Macronutrient Distribution

The overarching goals of MNT in diabetes are to attain individualized glycemic, blood pressure, and lipid targets while preventing or decelerating microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary artery disease, peripheral arterial disease, stroke) complications.

Clinical Therapeutic Targets for Non-Pregnant Adults

• Glycemic Targets: $\text{HbA1c} < 7.0\%$ ($< 53\text{ mmol/mol}$) for most non-pregnant adults; preprandial capillary plasma glucose $80 - 130\text{ mg/dL}$ ($4.4 - 7.2\text{ mmol/L}$); peak postprandial capillary plasma glucose $< 180\text{ mg/dL}$ ($< 10.0\text{ mmol/L}$).
• Blood Pressure: $< 130/80\text{ mmHg}$.
• Lipid Targets: $\text{LDL-C} < 100\text{ mg/dL}$ (or $< 70\text{ mg/dL}$ in individuals with established atherosclerotic cardiovascular disease); $\text{HDL-C} > 40\text{ mg/dL}$ in men, $> 50\text{ mg/dL}$ in women; Serum Triglycerides $< 150\text{ mg/dL}$.

Evidence-Based Macronutrient Allocation

• Carbohydrates: 45% to 60% of total energy expenditure. Emphasize low glycemic index (GI), nutrient-dense, fiber-rich sources (legumes, intact whole grains, non-starchy vegetables). Daily dietary fiber intake must achieve 25 to 35 g/day (or $14\text{ g / } 1000\text{ kcal}$), with $\ge 10\text{ g}$ from soluble viscous fiber.
• Protein: 15% to 20% of total energy (approx. $0.8 - 1.0\text{ g/kg/day}$ for patients with normal renal function). In established diabetic nephropathy (microalbuminuria or reduced GFR), protein should be maintained at $0.8\text{ g/kg/day}$ to reduce glomerular hyperfiltration; excess protein ($> 20\%$ of total calories) increases renal solute load.
• Fats: 20% to 35% of total energy. Saturated fatty acids must be restricted to $< 7\%$ of total calories, trans fatty acids eliminated, and dietary cholesterol limited to $< 200\text{ mg/day}$. Replace saturated fats with monounsaturated fatty acids (MUFA, e.g., olive oil, canola oil, avocado) and polyunsaturated fatty acids (PUFA).

---

Meal Planning Tools: The FNRI Food Exchange Lists for Filipinos

In the Philippines, dietary prescription and meal planning standardly utilize the Food Exchange Lists for Meal Planning published by the Food and Nutrition Research Institute (FNRI-DOST). In this system, foods are clustered into seven exchange groups such that foods within the same list supply approximately identical quantities of carbohydrate, protein, fat, and energy:

---

Carbohydrate Counting: Basic vs. Advanced Protocols

Carbohydrate counting provides flexible meal planning rooted in the physiological fact that carbohydrate is the primary macronutrient driving postprandial blood glucose excursions:

1. Basic Carbohydrate Counting

• 1 Carbohydrate Choice / Serving = $15\text{ g}$ of Carbohydrate.
• Targets are expressed as choices per meal: adult women typically require 3 to 4 carbohydrate choices (45 to 60 g) per meal; adult men require 4 to 5 choices (60 to 75 g) per meal, with 1 to 2 choices (15 to 30 g) for planned snacks.

2. Advanced Carbohydrate Counting (Basal-Bolus Insulin Regimens)

Advanced carbohydrate counting coordinates precise rapid-acting insulin boluses (insulin lispro, aspart, or glulisine) with the grams of carbohydrate ingested, utilizing two critical mathematical algorithms:

A. Insulin-to-Carbohydrate Ratio (ICR) — The 500 Rule

The ICR defines the number of grams of carbohydrate covered by 1 unit of rapid-acting insulin: $\text{ICR (g CHO / unit insulin)} = \frac{500}{\text{Total Daily Dose (TDD) of Insulin}}$

$\text{Meal Bolus (units)} = \frac{\text{Grams of Carbohydrate Consumed}}{\text{ICR}}$

B. Insulin Sensitivity Factor (ISF) / Correction Factor — The 1800 Rule

The ISF quantifies the anticipated drop in blood glucose (in $\text{mg/dL}$) produced by 1 unit of rapid-acting insulin: $\text{ISF (mg/dL / unit insulin)} = \frac{1800}{\text{Total Daily Dose (TDD) of Insulin}}$ (Note: For regular soluble human insulin, the 1500 Rule is used: $\text{ISF} = 1500 / \text{TDD}$.)

$\text{Correction Bolus (units)} = \frac{\text{Current Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}}$

$\text{Total Mealtime Insulin Dose} = \text{Meal Bolus} + \text{Correction Bolus}$

Clinical Board Calculation Example

Clinical Scenario: A 32-year-old male with T1DM has a Total Daily Dose (TDD) of 60 units of rapid-acting insulin. His pre-lunch blood glucose is $230\text{ mg/dL}$, his target glucose is $110\text{ mg/dL}$, and he is eating a lunch containing $75\text{ g}$ of carbohydrate.

1. Calculate ICR: $\text{ICR} = 500 / 60 = 8.33\text{ g CHO/unit} \approx 8.3\text{ g/unit}$.
2. Calculate Meal Bolus: $75 / 8.33 = 9.0\text{ units}$.
3. Calculate ISF: $\text{ISF} = 1800 / 60 = 30\text{ mg/dL per unit}$.
4. Calculate Correction Bolus: $(230 - 110) / 30 = 120 / 30 = 4.0\text{ units}$.
5. Calculate Total Lunch Bolus: $9.0 + 4.0 = 13.0\text{ units}$ of rapid-acting insulin.

---

Hypoglycemia Management and Nocturnal Glycemic Phenomena

Hypoglycemia Management: The "Rule of 15"

Hypoglycemia is defined as a blood glucose concentration $< 70\text{ mg/dL}$ ($< 3.9\text{ mmol/L}$):

1. Ingest $15\text{ g}$ of fast-acting simple carbohydrate (e.g., $1/2\text{ cup}$ [$120\text{ mL}$] fruit juice or regular soda, 3 to 4 commercial glucose tablets, 1 tablespoon [$15\text{ g}$] white table sugar dissolved in water, or 1 tablespoon honey).
2. Wait 15 minutes while resting quietly.
3. Recheck capillary blood glucose.
4. If blood glucose remains $< 70\text{ mg/dL}$, repeat administration of $15\text{ g}$ fast-acting carbohydrate and recheck in 15 minutes.
5. Once blood glucose normalizes ($\ge 70\text{ mg/dL}$), if the next scheduled meal is $> 1\text{ hour}$ away, the patient must consume a snack containing complex carbohydrate and protein (e.g., crackers with cheese, bread with peanut butter) to sustain euglycemia.

Dawn Phenomenon vs. Somogyi Effect

Patients presenting with severe fasting morning hyperglycemia ($> 200\text{ mg/dL}$) require definitive differential diagnosis via a 3:00 AM blood glucose check:

---

Medical Nutrition Therapy for Endocrine Disorders

1. Hypothyroidism (Hashimoto's Thyroiditis / Post-Ablative)

• Metabolic Profile: Substantially depressed Basal Metabolic Rate (BMR decreased by 20% to 40%) leading to hypothermia, fatigue, fluid retention (myxedema), dyslipidemia (impaired LDL receptor clearance), and constipation.
• MNT Guidelines: Prescribe a nutrient-dense, calorie-controlled diet to prevent excess weight gain; provide generous dietary fiber (25 to 35 g/day) and fluids (2.0 to 2.5 L/day) to manage constipation; ensure adequate iodine (via iodized salt under RA 8172) and selenium (co-factor for iodothyronine deiodinases converting $T_4$ to active $T_3$).
• Crucial Drug-Nutrient Interaction: Synthetic levothyroxine ($T_4$) must be taken on an empty stomach with plain water at least 30 to 60 minutes before breakfast. It must be strictly separated by at least 4 hours from calcium carbonate supplements, iron salts, soy protein formulas, and high-fiber supplements, which form insoluble chelates and abolish drug absorption.

2. Hyperthyroidism (Graves' Disease / Toxic Multinodular Goiter)

• Metabolic Profile: Marked hypermetabolism (BMR elevated by 50% to 100%), severe somatic protein breakdown, muscle wasting, tremors, tachycardia, osteoporosis due to osteoclastic bone resorption, and polyphagia with rapid weight loss.
• MNT Guidelines: High-energy diet ($35 - 40\text{ kcal/kg/day}$, often requiring 3,000 to 4,000 kcal/day); high-protein intake ($1.5 - 2.0\text{ g/kg/day}$) to restore somatic nitrogen stores; frequent nutrient-dense meals and between-meal snacks; generous calcium (1,200 to 1,500 mg/day) and Vitamin D supplementation to protect bone mineral density; complete elimination of caffeine and stimulants that exacerbate tachycardia.

3. Polycystic Ovary Syndrome (PCOS)

• Metabolic Profile: Hyperandrogenism, chronic anovulation, and polycystic ovarian morphology tightly linked to peripheral insulin resistance (present in 50% to 70% of lean and obese women) and compensatory hyperinsulinemia. Hyperinsulinemia stimulates ovarian theca cell androgen production and suppresses hepatic sex hormone-binding globulin (SHBG) synthesis, worsening clinical hirsutism and central adiposity.
• MNT Guidelines:
  • Modest weight loss of 5% to 10% of baseline body weight significantly restores ovulatory cycles and improves insulin sensitivity.
  • Anti-inflammatory, low glycemic index / low glycemic load dietary pattern (Mediterranean-style diet).
  • Balanced macronutrient distribution: Moderate complex carbohydrates (40% to 45% of energy), high fiber ($> 25\text{ g/day}$), lean protein (20% to 25%), and healthy fats rich in omega-3 fatty acids and MUFA (30% to 35%) to reduce visceral adiposity.
  • Targeted supplementation with myo-inositol (2 to 4 g/day) and d-chiro-inositol (40:1 physiological ratio) functions as a secondary messenger for insulin signaling, improving ovulatory function and metabolic markers.